BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Federal Trade Commission Slams Actelion Pharmaceuticals US, Inc. (ATLN.VX) for Withholding Samples


3/13/2013 7:31:02 AM

Should a brand-name drugmaker be required to sell samples of its medicine to an aspiring generic rival when its medicine was approved with a Risk Evaluation and Mitigation Strategy? What if the brand-name drugmaker argues that its REMS could be threatened by relinquishing strict control of its medicine? And what about the notion that a company should not be forced to do business with another company if it chooses not to do so? The issue has grown increasingly contentious and, last summer, language designed to sort out those questions nearly found its way into the Food and Drug Administration Safety and Innovation Act. Generic drugmakers and their allies, including some insurers and pharmacy benefit managers, complain that brand-name drugmakers use the strict distribution provisions of the REMS regulation as an excuse not to provide samples needed for bioequivalence testing. Now, though, the US Federal Trade Commission has sided with generic drugmakers. The agency has just filed a brief in one such case to argue that brand-name drugmakers that withhold samples from generic drugmakers are stifling competition. The case involves Actelion Pharmaceuticals, which is trying to prevent Apotex and Roxane Laboratories from selling generic versions of its Tracleer drug for treating pulmonary arterial hypertension. In a lawsuit filed last September, Actelion notes its drug is distributed only through pharmacies, physicians and healthcare settings that are “speically certified and bound by contract to follow a strict protocol to monitor and protect patient health… Any harm caused by the potential misuse of Tracleer during testing by a generic could have a significant impact on Actelion and Tracleer’s reputation and standing in the marketplace.” Actelion charges that both Apotex and Roxane sent threatening letters asserting the brand-name drugmaker was obligated to provides samples, and goes on to argue that there is no requirement for providing samples to generic drugmakers and, in fact, is prevented from doing so under REMS stipulations. Actelion also notes that Congress twice failed to pass legislation that contained such requirements but ultimately failed to do so.

Read at Pharmalot
Read at News Release
Read at News Release

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES